Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GI Transit of Ritlecitinib MR Capsule
NCT06369454Phase 1Completed
- Sponsor
- Pfizer
- Start
- May 2024
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ritlecitinib tosilate in alopecia areata (2 arms), sponsored by Pfizer. Primary endpoints: Site of capsule disintegration and MR microsphere dispersion up to 48 hours, Gastric emptying time up to 48 hours and 4 more. Started May 2024; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT06369454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06369454.